Eli Lilly’s Mounjaro revenue is just modern-day oil money extraction
By Josie Calloway · Reporting from Pittsburgh ·
The quarterly earnings report is supposed to tell us about market health; instead, it’s another flashing neon sign of where America's care infrastructure has failed—and who gets rich from it.
When Profit Becomes Infrastructure
The quarterly earnings report is supposed to tell us about market health; instead, it’s another flashing neon sign of where America's care infrastructure has failed—and who gets rich from it. Eli Lilly posted a staggering Q2 revenue of $22.97 billion, easily topping estimates, and raised its full-year forecast to between $85 billion and $87 billion. While David Ricks told CNBC that the company was in "a better position than this," what he really meant is that the global demand for weight-loss drugs like Mounjaro and Zepbound has created a new kind of resource monopoly. The core mechanism here isn't medicine; it’s capital flow, driven by scarcity—the scarcity of effective treatment that bypasses decades of systemic failure.
A New Kind of Black Gold
The sheer scale is breathtaking: Mounjaro’s worldwide revenue rose 91% to $9.94 billion in the quarter. This isn't just a drug; it's an economic force, making up nearly 65% of Lilly’s reported Q2 revenue (aol.com). The market sees this as "differentiated growth" (Citi analysts cited by aol.com), but I see something far more archaic. We are witnessing the emergence of modern-day oil money, echoing the unprecedented capital flow generated by the Discovery of oil in Texas. In 1930, that discovery fundamentally restructured American industry; today, these GLP-1 drugs are doing the same thing—restructuring our healthcare economy around a single, blockbuster mechanism. The profit motive has found its most lucrative vein yet.
Who Pays for the Pipeline?
The numbers tell us everything we need to know about who pays and who suffers. Lilly’s Q2 adjusted earnings per share of $8.38 beat expectations significantly (LSEG data). But while they celebrate their market dominance—holding 60.9% share in the U.S. obesity and diabetes drug market—they conveniently omit the systemic cost. The global GLP-1 use estimate is expected to rise from 20 million patients last year to 30 million by 2026, creating a massive pipeline of revenue for them. Yet, this "cure" remains tied up in complex coverage rules and high costs that only Medicare's $50 copay helps mitigate—a bandage on a hemorrhage. The quietest patient here isn’t the one with Type 2 diabetes; it’s the person who has to navigate this profit-fueled system just to afford basic care, let alone these billion-dollar treatments.
This is not an innovation story; it's an extraction narrative. We are watching the private sector treat human biology like a geological deposit waiting for the next boom cycle. The precedent of the East Texas Oil Field shows that when a single resource is found—be it oil or metabolic intervention—the downstream industries reorganize entirely to service the capital flow, leaving everything else secondary.
The promise of medicine must never be measured in quarterly earnings reports. When pharmaceutical giants treat human need like an untapped reserve, they don’t build public health infrastructure; they simply deepen their own corporate wells.